Intracameral more effective than subconjunctival cefuroxime

Article

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Intracameral cefuroxime is a safe alternative to subconjunctival cefuroxime and leads to a lower rate of endophthalmitis, claims a study published in the March 2008 issue of the Journal of Cataract & Refractive Surgery.

Patrick Yu-Wai-Man and colleagues at the Sunderland Eye Infirmary, UK, performed a retrospective analysis of all presumed infectious endophthalmitis cases from January 1, 2000, to December 31, 2006, and compared the rate of presumed infectious endophthalmitis in patients receiving subconjunctival cefuroxime with those receiving intracameral cefuroxime at the end of surgery.

The study, whose purpose was to compare the efficacy of intracameral cefuroxime versus subconjunctival cefuroxime in reducing the rate of endophthalmitis after cataract surgery, included 36 743 phacoemulsification cataract procedures, with a mean rate of presumed infectious endophthalmitis of 0.95 per 1000 cases. The incidence of endophthalmitis was significantly higher in the subconjunctival cefuroxime group than in the intracameral cefuroxime group.

Overall, the researchers found that intracameral cefuroxime was a safe alternative to subconjunctival cefuroxime and led to a lower rate of endophthalmitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.